Sanofi wins second bellwether trial over cancer drug Taxotere

0 5
  • Verdict is second bellwether win for drugmaker
  • More than 12,000 lawsuits declare permament hair loss linked to drug

The firm and regulation agency names proven above are generated robotically based mostly on the textual content of the article. We are enhancing this function as we proceed to check and develop in beta. We welcome suggestions, which you’ll present utilizing the suggestions tab on the proper of the web page.

(Reuters) – Sanofi supplied ample warning to a Louisiana lady that its chemotherapy drug Taxotere may trigger everlasting hair loss, a jury discovered late Thursday following a trial in New Orleans federal courtroom.

Sanofi has now gained each take a look at circumstances, or bellwethers, which have gone to trial in a mass tort litigation over the drug, which is pending earlier than U.S. District Judge Jane Triche Milazzo of the Eastern District of Louisiana.

“While disappointed in the result, we are confident that the evidence against Sanofi will result in positive verdicts for plaintiffs around the country in the future,” Chris Coffin of Pendley, Baudin & Coffin, a lawyer for plaintiff Elizabeth Kahn and different plaintiffs within the litigation, stated in an electronic mail. He stated Kahn would enchantment.

Register now for FREE limitless entry to reuters.com

“The jury’s decision is incredibly meaningful and reinforces that our client’s warning labels were adequate,” Hildy Sastre of Shook, Hardy & Bacon, who represented Sanofi at trial, stated in a press release.

Kahn sued Sanofi in 2016, alleging that she suffered everlasting hair loss, or alopecia, after being handled with Taxotere starting in 2008 for breast cancer.

She stated Sanofi had information that the drug may trigger everlasting hair loss, relatively than the non permanent hair loss frequent with chemotherapy medicine however had failed to check the danger totally or to warn medical doctors adequately.

Kahn stated that if she had recognized the drug carried the danger, she would have mentioned different choices along with her physician.

More than 12,000 product legal responsibility circumstances are pending earlier than Milazzo within the MDL in opposition to drugmakers, together with Sanofi, that manufactured and distributed Taxotere or generic variations of the chemotherapy drug, docetaxel.

Sanofi can also be dealing with lawsuits in state courts in New Jersey, California, and Delaware. Mississippi’s lawyer normal has sued the pharmaceutical firm over its advertising and marketing of the drug.

Sanofi gained the primary bellwether trial in September 2019.

The case is In re Taxotere (Docetaxel) Products Liability Litigation, U.S. District Court for the Eastern District of Louisiana, No. 16-md-02740.

For Kahn and different plaintiffs: Dawn Barrios of Barrios, Kingsdorf & Casteix, John Olinde of Chaffe McCall, Douglas Moore of Irwin Fritchie Urquhart & Moore, Chris Coffin of Pendley, Baudin & Coffin and others

For Sanofi: Hildy Sastre of Shook, Hardy & Bacon and others

Read extra:

Sanofi cannot escape second bellwether trial over Taxotere

Sanofi wins first bellwether trial in Taxotere litigation

Register now for FREE limitless entry to reuters.com
Brendan Pierson

Brendan Pierson experiences on product legal responsibility litigation and on all areas of well being care regulation. He will be reached at brendan.pierson@thomsonreuters.com.

The logo of Sanofi is seen during the annual results news conference in Paris, France, February 6, 2020. REUTERS/Benoit Tessier

Leave A Reply

Your email address will not be published.